Excited to have updated interim data results from our ANQUR Phase 1/2 clinical trial evaluating QRL-201 in #ALS patients that indicate a dramatic slowing of disease in sporadic ALS featured in @biospace. QurAlis' CEO and founder @Roet_Kasper recently presented these updated interim data results including ALSFRS-R, pNfH, and NfL data at @TargetALS_fdn Annual Meeting, which can be found in QurAlis' corporate presentation on our website under Presentations and Publications. #neurodegenerativediseases #neurologicaldiseases https://t.co/vtkLEJqQNu
Today marks the beginning of #ALSAwarenessMonth—a time to come together in support of those affected by amyotrophic lateral sclerosis (#ALS), also known as Lou Gehrig’s disease.
While individuals and families impacted by ALS remain at the forefront of our mission year-round, this month offers a meaningful opportunity to unite in celebrating the ALS community: to honor those living with ALS, remember those we’ve lost, and strengthen efforts to advance research and policy change.
At QurAlis, we are committed to developing #precisionmedicine therapies aimed at slowing and ultimately stopping this devastating disease. Together, through awareness, advocacy, and continued investment in research, we move closer to new treatments—and one day, a cure.
#neurodegenerativediseases #neurologicaldiseases
@bcathleticdept They are giving the max in the new NIL construct. Maybe you should pony up instead of complaining. That’s the issue. Alumni can supplement but aren’t doing it.
We are pleased to share that Vikas Sharma, QurAlis' CBO, and Jason Parker Brown, our CFO, are participating at the 2025 Citizens JMP Life Sciences Conference being held today and tomorrow (May 7-8, 2025) in New York. They will present a company overview tomorrow, May 8, 2025 at 2:30pET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
I repeat that every FDA reviewer and senior staff should be required by law to visit one afflicted patient with every single disease they review (with extra pay even.). Every day should be about the patients.
QurAlis is excited to announce positive topline data from our Phase 1 clinical trial of QRL-101 evaluating biomarkers of #ALS and #epilepsy in healthy volunteers (QRL-101-05; NCT06681441). Results demonstrated that QRL-101 has the potential to provide a therapeutic effect in both diseases. #Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in both sporadic and genetic forms of ALS, with the majority caused by the mis-splicing of the KCNQ2 gene in the pre-mRNA. Kv7 is also a clinically validated target to regulate the hyperexcitable state in epilepsy. Read more in our press release at https://t.co/7w36M5V4qB #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
Proud to have QurAlis sponsor the Walk to Defeat ALS Boston 2024. Although I will be walking virtually - looking forward to showing support for people living with ALS and their families.
QurAlis is proud to sponsor and participate in this year's @alsassociation's Walk to Defeat ALS Boston 2024 to raise funds to support #ALS research, as well as provide support to people living with ALS and their families. QurAlis has participated in this annual Walk for many years as it aligns with our mission to help people living with ALS. The Walk is Sunday, October 20, 2024 at @UMassBoston. Come join the QurAlis Qrew to Walk to Defeat ALS! #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://t.co/nqYOqGNvlb
QurAlis Presents! QurAlis' CEO and co-founder @RoetKasper was featured on a panel at the @IamBiotech BIO Investor Forum held this week in San Francisco. The panel, 'Expansion of Neurodegenerative Disease Targets and Pipelines,' moderated by Selina Koch, PhD, executive editor and head of intelligence & research at @BioCentury Inc., discussed the latest advancements in diverse approaches to #neurodegenerativediseases. #precisionmedicine #neurologicaldiseases
QurAlis is proud to sponsor the Northeast ALS Consortium (NEALS) 2024 Annual NEALS Meeting which brings together researchers, clinicians, industry leaders, and individuals with lived #ALS experience to discuss the latest advancements in ALS research and treatment. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://t.co/VLZZL16Tp2
QurAlis joins the rest of the world today to celebrate inviduals living with #FragileX syndrome (#FXS) and families and friends impacted by FXS, as well as raise awareness as we advance research toward finding effective #precisionmedicine treatments and ultimately a cure. FXS is a rare, genetic #neurologicaldisease that is the leading inherited form of intellectual disability and a known cause of #autism. There are no disease-modifying therapies currently available for FXS. #WorldFragileXDay #NationalFragileXAwarenessDay #NationalFragileXAwarenessMonth